Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

Core Insights - Pfizer Inc. announced positive topline results from the Phase 2b VESPER-3 study for its GLP-1 receptor agonist PF'3944, focusing on monthly maintenance dosing for adults with obesity or overweight without type 2 diabetes [1] Group 1 - The study aimed to demonstrate that PF'3944 could achieve continued weight loss when switching from weekly to monthly subcutaneous injections [1]